Lee J H, Lee C W, Park S W, Hong M K, Kim J J, Rhee K S, Park S J
Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea.
Clin Cardiol. 2001 Aug;24(8):551-5. doi: 10.1002/clc.4960240806.
Many patients with in-stent restenosis (ISR) are angina-free, but the optimal treatment for these patients remains uncertain.
In cases with asymptomatic moderate noncritical ISR. deferral of the intervention may be safe and associated with favorable clinical outcome.
We evaluated the long-term clinical outcome of asymptomatic patients (Group 1, n = 98) with moderate noncritical ISR (< 70% diameter stenosis) after intervention was deferred, and compared it with that of patients (Group 2, n = 655) without restenosis. After repeat angioplasty was deferred, all patients were treated medically and later underwent angioplasty only in the case of clinical recurrence.
Baseline characteristics were similar between the two groups. Clinical follow-up was available in all patients at 26.3+/-15.9 months. Twenty patients died during the follow-up: 1 in Group 1 and 19 in Group 2. Target lesion revascularization was performed in 3 patients in Group 1 and 11 patients in Group 2 during follow-up (p = NS), and new lesion revascularization in 2 patients in Group 1 and 27 patients in Group 2 (p = NS). Event-free survival rate (cardiac death, nonfatal myocardial infarction, repeat revascularization) was 86.7+/-6.1% in Group 1 and 84.8+/-2.2% in Group 2 at the end of follow-up (p = NS). Major adverse cardiac events were only associated with the presence of diabetic mellitus (hazards ratio 2.65, 95% confidence interval [CI] 1.48-4.73, p<0.01). The percentage of patients receiving antianginal medication was similar between the two groups at the end of the study (p = NS).
Asymptomatic patients with moderate noncritical ISR have a good prognosis and similar clinical outcome as those without ISR, suggesting that it may be safe to defer repeat angioplasty in these patients until angina recurrence.
许多支架内再狭窄(ISR)患者无心绞痛症状,但此类患者的最佳治疗方案仍不明确。
对于无症状的中度非重度ISR患者,延迟干预可能是安全的,且与良好的临床结局相关。
我们评估了延迟干预后无症状的中度非重度ISR(直径狭窄<70%)患者(第1组,n = 98)的长期临床结局,并将其与无再狭窄患者(第2组,n = 655)的结局进行比较。在延迟重复血管成形术后,所有患者接受药物治疗,仅在临床复发时才进行血管成形术。
两组患者的基线特征相似。所有患者的临床随访时间为26.3±15.9个月。随访期间有20例患者死亡:第1组1例,第2组19例。随访期间,第1组有3例患者、第2组有11例患者进行了靶病变血管重建(p = 无显著性差异),第1组有2例患者、第2组有27例患者进行了新病变血管重建(p = 无显著性差异)。随访结束时,第1组的无事件生存率(心源性死亡、非致命性心肌梗死、重复血管重建)为86.7±6.1%,第2组为84.8±2.2%(p = 无显著性差异)。主要不良心脏事件仅与糖尿病的存在相关(风险比2.65,95%置信区间[CI] 1.48 - 4.73,p<0.01)。研究结束时,两组接受抗心绞痛药物治疗的患者百分比相似(p = 无显著性差异)。
无症状的中度非重度ISR患者预后良好,临床结局与无ISR患者相似,这表明在这些患者心绞痛复发之前延迟重复血管成形术可能是安全的。